Back to results
US 12,460,006 B2Granted
Antibodies against integrin alpha 11 beta 1
AssigneeMomenta Pharmaceuticals, Inc.
InventorsElma Kurtagic, James W. Meador, III, Christopher Beneduce, Jr.
Life of this patent
Estimating the term…
Abstract
The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 (α11β1), as well as methods of making and using such antibodies.
Claims9
An anti-integrin alpha 11 beta 1 (α11β1) antibody, or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises:
- (1) a heavy chain comprising a heavy chain complementarity determining region 1 (CDRH1), a heavy chain complementarity determining region 2 (CDRH2), and a heavy chain complementarity determining region 3 (CDRH3) and (2) a light chain comprising a light chain complementarity determining region 1 (CDRL1), a light chain complementarity determining region 2 (CDRL2), and a light chain complementarity determining region 3 (CDRL3), and wherein
- the CDRH1 comprises the sequence GYTFTSYG (SEQ ID NO:
- 439),
- the CDRH2 comprises the sequence ISAYNGNT (SEQ ID NO:
- 265),
- the CDRH3 comprises the sequence VTGITGTTIDP (SEQ ID NO:
- 267),
- the CDRL1 comprises the sequence QSISSY (SEQ ID NO:
- 216),
- the CDRL2 comprises the sequence DAS (SEQ ID NO:
- 269), and
- the CDRL3 comprises the sequence QQYNNWPQT (SEQ ID NO:
- 271).
10 more elements
Dependencies are inferred from the claim text.